Goldline Pharmaceutical Key Ratios
BSE: 544759
₹40.90
₹0.90
(2.25%)
As on 01-Sep-2026IST
Market cap
₹39 Cr
Revenue (TTM)
₹31 Cr
P/E Ratio
9.5
P/B Ratio
1.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 11.20 | 16.27 | -- |
| EBIT | -- | -- | 17.81 | 49.80 | -- |
| Net Profit | -- | -- | 45.26 | 152.22 | -- |
| EPS | -- | -- | 45.26 | 140.73 | -- |
| Book Value | -- | -- | 47.19 | 38.38 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-26 | Mar-25 | Mar-24 |
| EBIT-Margin
| 20.06 | -- | 21.92 | 20.69 | 17.57 |
| Net Margin
| 13.20 | -- | 13.20 | -- | -- |
| Return on equity
| 38.03 | -- | 39.41 | 39.06 | 35.62 |
| Return on Capital
| 27.53 | -- | 30.60 | 28.82 | 23.18 |
| Return on Assets
| 11.68 | -- | 14.98 | 11.54 | 8.53 |
| Debt to Equity (x)
| -- | -- | 0.64 | 1.08 | 1.42 |
Profitability
ROCE
30.60
Higher than Peers by 14.52
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
30.60
|
28.82
|
23.18
|
12.17
|
--
|
|
Peer Median
|
16.08
|
3.84
|
5.02
|
9.20
|
--
|
ROE
39.41
Higher than Peers by 24.50
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
39.41
|
39.06
|
35.62
|
6.28
|
--
|
|
Peer Median
|
14.91
|
5.08
|
1.59
|
9.09
|
--
|
ROA
14.98
Higher than Peers by 6.58
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
14.98
|
11.54
|
8.53
|
1.32
|
--
|
|
Peer Median
|
8.40
|
2.19
|
1.46
|
2.77
|
--
|
EBIT Margin
21.92
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
21.92
|
20.69
|
17.57
|
10.25
|
--
|
|
Peer Median
|
--
|
2.93
|
3.78
|
4.14
|
--
|
Net Margin
13.20
Higher than Peers by 4.99
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
13.20
|
10.10
|
7.66
|
1.29
|
--
|
|
Peer Median
|
8.20
|
1.96
|
3.27
|
13.99
|
--
|
Cash Profit Margin
13.97
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
13.97
|
10.99
|
8.36
|
2.18
|
--
|
|
Peer Median
|
--
|
0.00
|
0.00
|
0.00
|
--
|
Revenue Growth
11.20
--
Year on year growth in net sales
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
11.20
|
19.05
|
18.73
|
--
|
--
|
|
Peer Median
|
--
|
50.75
|
56.32
|
1,43,500.00
|
--
|
EBIT Growth
17.81
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
17.81
|
40.24
|
103.45
|
--
|
--
|
|
Peer Median
|
--
|
75.04
|
59.55
|
-70.24
|
--
|
Net Profit Growth
45.26
--
Year on year growth in profit after tax
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
45.26
|
56.94
|
603.82
|
--
|
--
|
|
Peer Median
|
--
|
39.96
|
-8.68
|
-48.33
|
--
|
EPS Growth
45.26
--
Year on year growth in earnings per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
45.26
|
56.94
|
511.97
|
--
|
--
|
|
Peer Median
|
--
|
-21.00
|
--
|
--
|
--
|
Book Value Growth
47.19
--
Year on year growth in book value per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
47.19
|
39.53
|
48.37
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.64
No difference
Total debt / Net worth
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
0.64
|
1.08
|
1.42
|
1.84
|
--
|
|
Peer Median
|
0.64
|
--
|
0.63
|
--
|
--
|
Short term debt to equity ratio
0.42
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
0.42
|
0.55
|
0.73
|
0.84
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.15
No difference
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
2.15
|
1.98
|
1.92
|
1.87
|
--
|
|
Peer Median
|
2.15
|
2.47
|
2.33
|
5.05
|
--
|
Quick Ratio
1.64
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
1.64
|
1.40
|
1.18
|
1.27
|
--
|
|
Peer Median
|
--
|
1.68
|
10.32
|
6.03
|
--
|
Interest Coverage
4.70
No difference
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
4.70
|
2.98
|
2.57
|
1.25
|
--
|
|
Peer Median
|
4.70
|
2.66
|
2.65
|
2.05
|
--
|
Operating Efficiency
Debtors to sales
51.70
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
51.70
|
38.11
|
40.83
|
43.47
|
--
|
|
Peer Median
|
--
|
15.37
|
42.99
|
49.21
|
--
|
Asset Turnover
1.13
--
Sales / Average Total Assets
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
1.13
|
1.14
|
1.11
|
1.02
|
--
|
|
Peer Median
|
--
|
1.51
|
1.33
|
0.50
|
--
|
Receivable days
156.90
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
156.90
|
132.15
|
141.33
|
158.65
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
75.99
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
75.99
|
92.81
|
99.60
|
98.76
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
64.86
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
64.86
|
64.28
|
79.87
|
57.32
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
168.03
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
168.03
|
160.68
|
161.06
|
200.09
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
26.55
|
65.30
|
159.13
|
107.97
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
1.86
|
2.35
|
3.26
|
2.54
|
--
|
EV/EBITDA
2.44
Lower than Peers by 12.88
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
2.44
|
3.06
|
3.36
|
6.60
|
--
|
|
Peer Median
|
15.32
|
53.35
|
29.43
|
2.43
|
--
|
Market Cap
--
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
133
|
30
|
20
|
13
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
